CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis [Letter]

Zainarda, Hasta Handayani Idrus
Journal of multidisciplinary healthcare · 2024 · vol. Volume 17 , pp. 405–406 · doi:10.2147/jmdh.s460854 · PMID:38292920 · PMC10826712 · W4391258217
article OA: gold CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This letter discusses a study showing shorter thrombin time in adenomyosis patients compared to leiomyoma and control groups, highlighting the importance of monitoring coagulation parameters with elevated CA125.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This paper is a letter responding to Yang et al, highlighting findings that CA125 levels are significantly higher in patients with adenomyosis than in leiomyoma and control groups, alongside shorter thrombin time in the adenomyosis group compared with the other groups. The letter emphasizes the relevance of CA125-associated changes in coagulation parameters (APTT and TT) to hypercoagulability and notes a limitation that CA125 alone may not be a sufficiently strong predictor, recommending further investigation with larger samples. It also argues that specificity and sensitivity could improve by using combinations of CA125 with other blood-based markers, citing prior studies on biomarker panels for surgical prediction. This paper is centrally about adenomyosis—specifically commenting on CA125-associated changes in APTT and thrombin time and their relationship to hypercoagulability and thrombosis in adenomyosis patients.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We have read the paper by Yang et al on CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis. 1 We congratulate the authors for providing new information regarding the CA125 antigen in relation to hypercoagulability and thrombosis in adenomyosis patients.This is quite important because coagulation parameters must be detected on time and closely monitored to prevent thrombosis, besides that the CA125 antigen also has a pattern of changes in levels which is different for each patient after surgery, this can help medical personnel in determining the patient's prognosis after surgery. 2 The study conducted by Yang et al aimed to explore more deeply the changes and factors that influence the coagulation parameter, namely CA125, in patients with adenomyosis and obtained the results that CA125 levels in the adenomyosis group were significantly higher than in the leiomyoma group. 1 However, thrombin time was shorter in the adenomyosis group compared with the leiomyoma and control groups.The results obtained are in line with the objectives the author wants to achieve.However, it is necessary to consider using more than one antigen to increase the specificity and sensitivity of the examination carried out, for example we recommend the combination of MPV and CA125, RDW and CA125, because it can significantly help in increasing the accuracy of diagnosis by doctors. 3Other studies also reveal that the combination of CA125 and GLS or CA125, FASN and GLS can increase sensitivity, specificity and accuracy in predicting suboptimal cytoreductive surgery.It is hoped that this combination can help doctors provide better therapy. 4n conclusion, we agree that the shortening of APTT and TT related to CA125 shows the importance of early detection of coagulation parameters in patients with elevated CA125 levels to determine hypercoagulability and prevent thrombi in adenomyosis. 1 However, several studies have found that CA-125 is not a strong enough predictor if stands alone in diagnostic screening, but it requires a combination of several biomarkers which also play a role in predicting and preventing thrombosis, therefore it is necessary to carry out further research with larger samples so that the results of this research will continue to develop.
Full text 2,335 characters · extracted from pmc-nxml · 1 sections · click to expand

Dear

We have read the paper by Yang et al on CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis. 1 We congratulate the authors for providing new information regarding the CA125 antigen in relation to hypercoagulability and thrombosis in adenomyosis patients. This is quite important because coagulation parameters must be detected on time and closely monitored to prevent thrombosis, besides that the CA125 antigen also has a pattern of changes in levels which is different for each patient after surgery, this can help medical personnel in determining the patient’s prognosis after surgery. 2 The study conducted by Yang et al aimed to explore more deeply the changes and factors that influence the coagulation parameter, namely CA125, in patients with adenomyosis and obtained the results that CA125 levels in the adenomyosis group were significantly higher than in the leiomyoma group. 1 However, thrombin time was shorter in the adenomyosis group compared with the leiomyoma and control groups. The results obtained are in line with the objectives the author wants to achieve. However, it is necessary to consider using more than one antigen to increase the specificity and sensitivity of the examination carried out, for example we recommend the combination of MPV and CA125, RDW and CA125, because it can significantly help in increasing the accuracy of diagnosis by doctors. 3 Other studies also reveal that the combination of CA125 and GLS or CA125, FASN and GLS can increase sensitivity, specificity and accuracy in predicting suboptimal cytoreductive surgery. It is hoped that this combination can help doctors provide better therapy. 4 In conclusion, we agree that the shortening of APTT and TT related to CA125 shows the importance of early detection of coagulation parameters in patients with elevated CA125 levels to determine hypercoagulability and prevent thrombi in adenomyosis. 1 However, several studies have found that CA-125 is not a strong enough predictor if stands alone in diagnostic screening, but it requires a combination of several biomarkers which also play a role in predicting and preventing thrombosis, therefore it is necessary to carry out further research with larger samples so that the results of this research will continue to develop. 2

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (4)

Source provenance

europepmc
last seen: 2026-06-27T06:13:33.955442+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-27T06:11:44.874715+00:00
License: CC0 · commercial use OK